1. siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn’s Disease. Russo I. et al. 2017. Transl Med UniSa. Jul; 17: 25–33. One common feature of inflammatory bowel diseases (IBD) is an increased risk of developing colorectal cancer. The chronic inflammation of these diseases can interfere in the cellular cycle, leading the intestinal cells to duplicate uncontrollably … Read More
August New Deal Reads
1. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Blakney AK et al. 2019. Gene Therapy Self-amplifying RNA (saRNA) therapies are at the forefront of new vaccine design, as they have been used to treat diseases like HIV or cancer. To make their effect saRNA molecules must go through the membrane of … Read More
May New Deal Reads
A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function. De Vries L. C. S et al. Inflammatory Bowel Disease. 25 (4) 2019. Janus kinases (JAKs) are involved in the intestinal inflammation found in IBD. A common treatment for this disease is tofacitinib, a drug that inhibits different JAKs. Although this therapy is effective, it doesn’t target only … Read More
April New Deal Reads
1. Targeting JAK-STAT signal transduction in IBD. Soendergaard C. et al. Pharmacology & Therapeutics 192(2018): 100-111 Antibody-based biological drugs were a significant advance for IBD treatments, but unfortunately a high percent of patients doesn’t respond well to this therapy highlighting the need for alternative therapies. Recent studies have shown the great potential of JAK inhibitors to face this unmet medical … Read More
February New Deal Reads
In New Deal Reads we have prepared for you a selection of relevant papers in the field of IBD and nanotechnology so you can stay tuned with the new advances: 1. Local delivery of macromolecules to treat diseases associated with the colon, Bak A, .Ashford M, Brayden D.J. Journal: Advanced Drug Delivery Reviews in December 2018 The local delivery of … Read More
